Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Conclusions Patients with IPF and preserved lung volume (FVC >90% predicted) have the same rate of FVC decline and receive the same benefit from nintedanib as patients with more impaired lung volume. Trial registration number NCT01335464 and NCT01335477.
Source: Thorax - Category: Respiratory Medicine Authors: Tags: Open access, Interstitial lung disease Source Type: research